Genosyl is a drug owned by Vero Biotech Inc. It is protected by 25 US drug patents filed from 2020 to 2023. Out of these, 24 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 22, 2040. Details of Genosyl's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6758214 | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
Feb, 2022
(2 years ago) |
Expired
|
| US11554241 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US8226916 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US10124142 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US11383059 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US11291793 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US8821801 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US8609028 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US9956373 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US9522249 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 21 days from now) | Active |
| US10814092 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2025
(1 year, 2 months from now) | Active |
| US8057742 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2026
(1 year, 5 months from now) | Active |
| US7618594 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(2 years from now) | Active |
| US7947227 | Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(2 years from now) | Active |
| US7560076 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Apr, 2027
(2 years from now) | Active |
| US9701538 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2029
(4 years from now) | Active |
| US10926054 | Systems and devices for generating nitric oxide |
Aug, 2029
(5 years from now) | Active |
| US9604028 | Systems and devices for generating nitric oxide |
Aug, 2029
(5 years from now) | Active |
| US8944049 | Systems and devices for generating nitric oxide |
Aug, 2029
(5 years from now) | Active |
| US11511252 | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Sep, 2029
(5 years from now) | Active |
| US11103669 | Nitric oxide therapies |
Jun, 2030
(5 years from now) | Active |
| US8607785 | Systems and devices for generating nitric oxide |
Jul, 2030
(5 years from now) | Active |
| US10737051 | Nitrogen dioxide storage device |
Oct, 2035
(11 years from now) | Active |
| US10213572 | Nitrogen dioxide storage cassette |
Feb, 2036
(11 years from now) | Active |
| US11672938 | Start-up protocols for nitric oxide delivery device |
Jul, 2040
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Genosyl's patents.
Latest Legal Activities on Genosyl's Patents
Given below is the list of recent legal activities going on the following patents of Genosyl.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Jun, 2024 | US9522249 |
| Change in Power of Attorney (May Include Associate POA) | 23 May, 2024 | US8057742 |
| Email Notification | 23 May, 2024 | US8057742 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 10 Apr, 2024 | US10814092 |
| Email Notification | 23 Feb, 2024 | US10737051 |
| Change in Power of Attorney (May Include Associate POA) | 23 Feb, 2024 | US10737051 |
| Change in Power of Attorney (May Include Associate POA) | 09 Feb, 2024 | US8226916 |
| Email Notification | 09 Feb, 2024 | US8226916 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 31 Jan, 2024 | US10737051 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 17 Jan, 2024 | US8226916 |
US patents provide insights into the exclusivity only within the United States, but Genosyl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Genosyl's family patents as well as insights into ongoing legal events on those patents.
Genosyl's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Genosyl's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 22, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Genosyl Generics:
Nitric Oxide is the generic name for the brand Genosyl. 2 different companies have already filed for the generic of Genosyl, with Linde Gas Equip having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Genosyl's generic
About Genosyl
Genosyl is a drug owned by Vero Biotech Inc. It is used for treating pulmonary hypertension or hypoxia through nitric oxide delivery to the patient. Genosyl uses Nitric Oxide as an active ingredient. Genosyl was launched by Vero Biotech Inc in 2019.
Market Authorisation Date:
Genosyl was approved by FDA for market use on 20 December, 2019.
Active Ingredient:
Genosyl uses Nitric Oxide as the active ingredient. Check out other Drugs and Companies using Nitric Oxide ingredient
Treatment:
Genosyl is used for treating pulmonary hypertension or hypoxia through nitric oxide delivery to the patient.
Dosage:
Genosyl is available in gas form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 800PPM | GAS | Prescription | INHALATION |